Edwards Lifesciences (EW) Stock Forecast, Price & News

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View EW analyst ratings or view top-rated stocks.

18 brokerages have issued 1-year price targets for Edwards Lifesciences' shares. Their EW share price forecasts range from $66.00 to $110.00. On average, they expect the company's stock price to reach $92.30 in the next twelve months. This suggests a possible upside of 31.7% from the stock's current price.
View analysts price targets for EW or view top-rated stocks among Wall Street analysts.

Edwards Lifesciences' stock was trading at $74.61 at the beginning of 2023. Since then, EW shares have decreased by 6.0% and is now trading at $70.11.
View the best growth stocks for 2023 here.

Edwards Lifesciences saw a increase in short interest in September. As of September 15th, there was short interest totaling 12,700,000 shares, an increase of 18.1% from the August 31st total of 10,750,000 shares. Based on an average trading volume of 3,210,000 shares, the days-to-cover ratio is currently 4.0 days. Approximately 2.1% of the company's stock are short sold.
View Edwards Lifesciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our EW earnings forecast.

Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings results on Wednesday, July, 26th. The medical research company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.01. The medical research company earned $1.53 billion during the quarter, compared to analysts' expectations of $1.51 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 25.43% and a net margin of 24.56%. The firm's revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.63 EPS.
Read the conference call transcript.

ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), Global X Aging Population ETF (AGNG), First Trust Indxx Medical Devices ETF (MDEV), ETC 6 Meridian Quality Growth ETF (SXQG), BNY Mellon Sustainable US Equity ETF (BKUS), Goldman Sachs Future Health Care Equity ETF (GDOC) and Inspire 100 ETF (BIBL).

Shares of Edwards Lifesciences split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its third quarter 2023 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $0.55-$0.61 for the period, compared to the consensus earnings per share estimate of $0.63. The company issued revenue guidance of $1.44 billion-$1.52 billion, compared to the consensus revenue estimate of $1.47 billion.

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (125.25%), BlackRock Inc. (8.36%), State Street Corp (4.45%), Capital International Investors (4.44%), Alliancebernstein L.P. (3.37%) and Bank of New York Mellon Corp (2.91%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends.

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EW stock can currently be purchased for approximately $70.11.

Edwards Lifesciences (NYSE:EW) has a market capitalization of $42.62 billion and generates $5.38 billion in revenue each year. The medical research company earns $1.52 billion in net income (profit) each year or $2.26 on an earnings per share basis.

The company employs 17,300 workers across the globe.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.